Owen Caroline A
Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.
Int J Chron Obstruct Pulmon Dis. 2008;3(2):253-68. doi: 10.2147/copd.s2089.
Since the early 1960s, a compelling body of evidence has accumulated to show that proteinases play critical roles in airspace enlargement in chronic obstructive pulmonary disease (COPD). However, until recently the causative enzymes and their exact roles in pathologic processes in COPD have not been clear. Recent studies of gene-targeted mice in murine models of COPD have confirmed roles for proteinases not only in airspace enlargement, but also in airway pathologies in COPD. These studies have also shed light on the specific proteinases involved in COPD pathogenesis, and the mechanisms by which these proteinases injure the lung. They have also identified important interactions between different classes of proteinases, and between proteinases and other molecules that amplify lung inflammation and injury. This review will discuss the biology of proteinases and the mechanisms by which they contribute to the pathogenesis of COPD. In addition, I will discuss the potential of proteinase inhibitors and anti-inflammatory drugs as new treatment strategies for COPD patients.
自20世纪60年代初以来,大量令人信服的证据不断积累,表明蛋白酶在慢性阻塞性肺疾病(COPD)的气腔扩大中起关键作用。然而,直到最近,导致COPD病理过程的致病酶及其确切作用仍不明确。最近对COPD小鼠模型中基因靶向小鼠的研究证实,蛋白酶不仅在气腔扩大中起作用,而且在COPD的气道病变中也起作用。这些研究还揭示了参与COPD发病机制的特定蛋白酶,以及这些蛋白酶损伤肺的机制。它们还确定了不同类别的蛋白酶之间,以及蛋白酶与其他放大肺部炎症和损伤的分子之间的重要相互作用。本综述将讨论蛋白酶的生物学特性及其导致COPD发病机制的方式。此外,我将讨论蛋白酶抑制剂和抗炎药物作为COPD患者新治疗策略的潜力。